Search

Ya‘kub b. İshak Kindî (ö. 252/866?), üzüntü hastalığına dair müstakil bir risale yazan ilk Müslüman filozoftur. Onun el-Hile lidef’il-ahzân adlı risalesi, özellikle sonraki ahlak felsefesi eserlerinde üzüntü bahsinin temel referansı olmuştur. Kindî’nin üzüntünün tedavisi için önerdiği çarelerin tasavvufi ideallere ne derece hizmet ettiğini tespit etmeye çalıştığımız bu makalede öncelikle Müslüman filozoflar ile mutasavvıfların üzüntünün mahiyeti, sebepleri, sonuçları ve tedavi yollarına dair açıklamaları temsilcilerinin metinlerinden hareketle ele alınmıştır. Üzüntünün felsefi ve tasavvufi perspektifte ne ifade ettiği, nasıl karşılandığı anlaşılmaya çalışılmıştır. Filozofların başta dünya mutluluğunu sağlamaya yönelik olarak üzüntüyü engellemeyi, meydana geldiği takdirde gidermeyi önemsemelerine karşılık, mutasavvıfların davet etmemekle birlikte başa gelen üzüntüyü davetsiz bir misafir olarak rıza ile karşıladıkları görülmüştür. Kindî düşüncesinde üzüntü tedavisinin neticede yol üzerindeki engelleri kaldırması ve dünyevi bağlılığa mâni olması itibariyle sufinin kemale ermesine katkı sağladığını söylemek mümkündür. Üzüntü karşısındaki felsefi ve tasavvufi yaklaşım farkının en önemli tezahürü, bazı mutasavvıfların üzüntüye muhabbetle yaklaşmasıdır. Geçici dünyevi nimet ve makamlara bağlanmak ve elden çıkınca üzüntüye gark olmak Kindî açısından mutluluğa, mutasavvıflar açısından ruhun tasfiyesine manidir. Ruhun arındırılmaması, iki âlemde de mutsuzluğa sebep olacağı için felsefi tedavi yönteminin sonuçları bakımından tasavvufi ideallerle uyuştuğu söylenebilmektedir.

Objective: Heparin-induced thrombocytopenia (HIT) is a life threatening complication of heparin therapy, causing thrombosis. The aim of our study was to find out the frequencies of HIT antibody seroconversion and clinical HIT in Turkish medical patients on different forms of heparins. Materials and Methods: Our study included 61 patients who were on unfractionated heparin (UFH) (n: 37) and low molecular weight heparin (LMWH) (n: 24) therapies. The frequency of HIT antibody formation was determined by means of antigenic (ELISA), and functional assays (serotonin release assay-SRA). Results: The seroconversion rates in UFH and LMWH groups were found to be 18.9% and 4.1% (ELISA), and 8.1% and 4.1% (SRA), respectively. One patient (2.1%) on UFH therapy developed deep vein thrombosis. No thromboembolic event was observed in patients taking LMWH. Conclusion: Seroconversion rates by means of antigenic and functional assays and clinical HIT were more common in patients on UFH than patients on LMWH therapy.

Background. Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system and the main cause of disability in young people. Drug therapy cannot completely control many disabling symptoms in MS, such as cramps, pain, depression, and cognitive impairment. Non-invasive brain stimulation (NIBS) technology can be used as a tool to regulate changes in cortical excitability and plasticity in MS patients, thereby improving the disability symptoms that affect such patients. Aims. Our objective was to explore the effectiveness and safety of non-invasive brain stimulation in the treatment of fatigue in patients with multiple sclerosis. Methods. We performed a literature review in different databases: PubMed, Web of Science, Cochrane Library, Medline, Google Scholar. Full text articles that used NIBS for exercise performance improvement in athletes were included (only articles in English were found). We searched for articles available in each database until 30 October 2019. We used articles published in journals, randomized or pseudo-randomized, sham-controlled clinical trials to evaluate the effects of noninvasive brain stimulation (NIBS). The main result is the fatigue score before and after stimulation; the secondary result is the adverse event. Results. The general inverse variance method was used to aggregate data from cross-group and parallel group studies. A total of 14 studies (tDCS 11, TMS 2 and tRNS 1) which recruited 186 patients were included in the study. No qualified tACS, transcranial electrical therapy stimulation or non-invasive cortical electrical stimulation study with reduced impedance was found. The short-term and long-term therapeutic effects are for tDCS, TMS is significant, and TMS and tRNS are not superior to sham stimulation. Existing evidence supports the effectiveness of the 1.5 mA subgroup and the bilateral S1 subgroup of tDCS. Adverse events are mild and transient, but are comparable between real and sham stimulation. Conclusions. tDCS is a safe and effective way to treat fatigue in MS patients. However, there is further research needed to confirm our results in a large population and investigate the effectiveness of other NIBS subtypes. [ABSTRACT FROM AUTHOR]

Background. When transcranial direct current stimulation (tDCS) was reintroduced as a non-invasive brain stimulation technique, it had been known for more than 50 years that the main mechanism of action was the sub-threshold regulation of neuronal membrane potential, which depended on changing the cortical excitability and activity through the current flow of the target neuron. In this review we concentrated on the progress made for tDCS in the last few years in sports, which so far has partially found entrance into the design of clinical studies, and on results obtained in recently conducted clinical pilot studies. Aims. Our objective was to analyze the effects of tDCS în sport exercises, for normal or high-level practitioners. Methods. We performed a literature review în different databases: PubMed, Web of Science, SCOPUS, SportDiscus, Google Scholar. Full text articles that used tDCS for exercise performance improvement in athletes were included (only articles in English were found). We searched for articles available in each database until 15 January 2018. We used articles published in journals, randomized sham controlled trials comparing anodal stimulation and cathodal stimulation to a sham / control for performance in isometric, isokinetic or dynamic strength exercise and whole-body exercise. Results. We included 23 studies that met our selection criteria, in which tDCS produced changes in cycling training for: the whole body (9 articles), for muscle strength in isometric exercise (7 articles), for maximal isometric voluntary contraction (MIVC) (2 articles), for isokinetic exercises (3 articles) and during dynamic exercise (2 articles). Conclusions. The anodal stimulation (a-tDCS) on the motor cortex (M1) had better results than sham stimulation especially for cycling exercises; consequently, more studies and attempts of different montages are needed. Interest in tDCS is constantly growing, as evidenced by the growing number of studies in recent years. Consequently, positive results will appear more and more with the discovery of optimal stimulation parameters. In other words research must continue for this therapy of the future to become a consistent therapeutic alternative, especially in performance athletes. [ABSTRACT FROM AUTHOR]

Background. Spasticity is well known as one of the most common after stroke complications, providing a series of negative effects including decreased range of motion, muscle spasm, different levels of contracture, local pain in the affected area. Aims. Clinical-functional evaluation of the short and medium term effect of ultrasonographically guided injections with botulinum toxin type A (TxB-A) on the spasticity of the upper limb in post-stroke patients and the quantification of effects on international scales of spasticity and functionality. Methods. The groups studied were composed of 60 patients, which were divided based on the doses provided in each muscle of the hand and wrist flexors (250 IU versus 333 IU). Every patient received a total dose of 1000 IU of TxB-A. The parameters that were assessed were: Modified Ashworth Scale (MAS) and Activities of Daily Living Scale (ADL), international scales for spasticity and functionality. The moments evaluated were: T0 (the initial time - injection time), T1 (one month after the injection) and T2 (3 months from T0 or 2 months from T1). Results. Evaluation of MAS and ADL scales from T0 to T1 and T2 for the 250 IU group shows great improvements at T1 on both scales, MAS (<0.001) and ADL (<0.001), while maintaining the efficacy at T2, MAS (p-value 0.214 ), ADL (p-value 0.166). Evaluation of MAS and ADL scales from T0 to T1 and T2 for the 333 IU group also shows effective improvements on both scales at T1, MAS (<0.001), ADL (<0.001), and T2, MAS (0.849), ADL (0.013). Correlations between the two groups, 250 IU vs 333 IU, performed for each of the scales used in the study evidenced better results at T1 in favor of the 333 IU group on both MAS (p-value 0.034) and ADL score (p-value 0.078), with the proportion maintained in favor of the 333 IU group at T2, MAS (p-value 0.024), ADL (p-value 0.035). Conclusions. a) TxB-A is efficient as a prime line treatment for spasticity, helping the patients in the muscle neurorehabilitation effort; b) TxB A is effective in reducing spastic muscle tone (MAS); c) TxB A is a useful asset in managing hand function (ADL). [ABSTRACT FROM AUTHOR]